Author:
Isacoff William H.,Reber Howard A.,Bedford Rudolph,Hoos William,Rahib Lola,Upfill-Brown Alexander,Donahue Timothy,Hines O. Joe
Funder
William H. Isacoff, MD Research Foundation for Gastrointestinal Cancer
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference58 articles.
1. American Cancer Society. Cancer Facts and Figures 2015. Atlanta: American Cancer Society; 2015.
2. Weinberg BA, Yabar CS, Brody JR, Pishvaian MJ. Current standards and novel treatment options for metastatic pancreatic adenocarcinoma. Oncology. 2015;29:809–19.
3. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefits with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFORINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
5. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778–85.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献